Bio-Techne (TECH) Scheduled to Post Earnings on Wednesday

Bio-Techne (NASDAQ:TECH) will be releasing its earnings data before the market opens on Wednesday, May 1st. Analysts expect Bio-Techne to post earnings of $0.40 per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Bio-Techne (NASDAQ:TECH) last posted its quarterly earnings results on Thursday, February 1st. The biotechnology company reported $0.33 earnings per share for the quarter, missing analysts’ consensus estimates of $0.36 by ($0.03). Bio-Techne had a net margin of 19.58% and a return on equity of 14.21%. The company had revenue of $272.60 million during the quarter, compared to analyst estimates of $277.48 million. On average, analysts expect Bio-Techne to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Bio-Techne Stock Up 1.4 %

Shares of Bio-Techne stock opened at $63.69 on Wednesday. The business has a fifty day simple moving average of $70.35 and a 200 day simple moving average of $68.61. The stock has a market cap of $10.01 billion, a PE ratio of 46.17, a price-to-earnings-growth ratio of 7.73 and a beta of 1.22. The company has a quick ratio of 3.03, a current ratio of 4.37 and a debt-to-equity ratio of 0.23. Bio-Techne has a 12 month low of $51.79 and a 12 month high of $89.91.

Bio-Techne Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, February 26th. Stockholders of record on Monday, February 12th were given a dividend of $0.08 per share. The ex-dividend date was Friday, February 9th. This represents a $0.32 annualized dividend and a dividend yield of 0.50%. Bio-Techne’s payout ratio is currently 23.19%.

Insider Buying and Selling

In other Bio-Techne news, Director Roeland Nusse sold 10,400 shares of the business’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $76.98, for a total value of $800,592.00. Following the sale, the director now owns 43,097 shares in the company, valued at approximately $3,317,607.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 4.10% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

TECH has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft cut their price target on shares of Bio-Techne from $85.00 to $82.00 and set a “buy” rating on the stock in a research report on Thursday, April 18th. Scotiabank assumed coverage on shares of Bio-Techne in a report on Thursday, February 8th. They issued a “sector outperform” rating and a $80.00 price target for the company. Stephens dropped their price objective on Bio-Techne from $92.00 to $87.00 and set an “overweight” rating on the stock in a research note on Friday, February 2nd. Stifel Nicolaus lowered Bio-Techne from a “buy” rating to a “hold” rating and set a $65.00 target price on the stock. in a report on Friday, February 2nd. Finally, Royal Bank of Canada lowered their price target on Bio-Techne from $85.00 to $75.00 and set a “sector perform” rating for the company in a report on Friday, February 2nd. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $83.90.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.